May 29, 2024

Antimicrobial Therapeutics Market High Growth Opportunities, Emerging Trends, Industry Review, Forecast Till 2031

Market Overview:

Antimicrobial therapeutics are pharmaceutical drugs used to treat and prevent infectious diseases caused by microorganisms such as bacteria, viruses, fungi, and parasites. The therapeutics include antibacterial, antiviral, antifungal, and antiparasitic drugs.

Market Dynamics:

The antimicrobial therapeutics market is expected to witness significant growth over the forecast period owing to rising prevalence of infectious diseases and increasing antimicrobial resistance. According to the World Health Organization (WHO), infectious diseases account for approximately 16% of global burden of diseases and 23% of deaths worldwide. Increasing resistance of microorganisms to existing antimicrobial drugs has resulted in demand for development of novel antimicrobial therapeutics. Furthermore, rising healthcare expenditure in developing economies is also expected to fuel market growth during the forecast period.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/antimicrobial-therapeutics-market-5845

Rising Incidence of Infectious Diseases is Driving Demand for New Antimicrobial Therapeutics

The incidence of infectious diseases has been increasing at an alarming rate globally. The emergence of multi-drug resistant microbial strains has made the treatment of many infectious diseases extremely challenging. This has created a big clinical need for new classes of antimicrobial drugs with novel mechanisms of action. According to WHO, antimicrobial resistance is one of the biggest threats to global health, food security, and development today. Developing effective antimicrobial therapeutics against drug-resistant microbial pathogens has become a top public health priority. As the threat of resistant microbial infections continues to grow, the demand for innovative solutions to treat such infections is also rising significantly, providing a strong driver for the growth of the antimicrobial therapeutics market.

Increasing R&D Investments from Pharmaceutical Companies

Pharmaceutical companies around the world have significantly ramped up their R&D investments focused on developing novel antimicrobial therapeutics over the past decade in response to the growing antimicrobial resistance crisis. Large pharmaceutical players are partnering with biotech startups and academic research institutions and allocating more capital to antimicrobial drug development programs. Government initiatives like Generating Antibiotic Incentives Now (GAIN) Act in the US are also incentivizing pharmaceutical investment in this area. Between 2010-2018, over US$8 billion were invested globally in R&D for new antibiotics, with investments growing at an annual rate of 11%. Rising investments indicate a promising pipeline of new antimicrobial candidates. Sustained R&D support in the coming years is expected to translate into new product approvals and commercial success, thereby driving further growth in the antimicrobial therapeutics market.

Stringent Regulatory Guidelines Can Deter Market Growth

Regulatory requirements for approval of new antimicrobial drugs have become extremely stringent in recent years due to safety concerns. Regulators are reluctant to approve broad-spectrum antimicrobials and insist on restricted indications to prevent misuse and curb antimicrobial resistance. For instance, the FDA now requires controlled distribution programs, restrictive labels and post-marketing trials for newly approved antibiotics. While intended to promote judicious use, restrictive policies can delay product launch, increase costs and limit viable market opportunities for drug developers. The lengthy and expensive drug development process along with regulatory hurdles discourage pharmaceutical investment in this fragile market to some extent. Developers also face pressure to earn back costs within a short exclusivity window, which can deter innovation. Stringent regulations thus remain a restraining factor impacting overall market growth trajectory.

Combination Therapies Present Significant Commercial Opportunities

Combination therapies using two or more antimicrobial drugs with different mechanisms have emerged as a promising strategy to combat multi-drug resistant microbial infections. Combinations help address resistance development and breath new life into older antibiotics. Developers are actively pursuing combination formulations involving existing antimicrobials as well as those containing both old and new drugs. For instance, last year the FDA approved the first ever combination of two generic antibiotics-vabomere- to treat complicated urinary tract and intra-abdominal infections. Combination antimicrobial therapeutics present significant commercial opportunities thanks to their enhanced clinical utility compared to single agents. As resistance issues mount, the demand for combination therapy options from healthcare providers is likely to increase tremendously in the coming years.

Increasing Adoption of Organism-specific Therapeutics

With growing understanding of microbial pathogenesis, modern drug development is increasingly focused on developing organism-specific rather than broad-spectrum antimicrobial therapeutics. Developers are designing drugs that selectively target certain virulence factors or cellular pathways unique to priority pathogens. This promising approach helps overcome non-specific toxicity, optimize treatment outcomes and minimize collateral effects like resistance development associated with broad-spectrum usage. For instance, newer therapeutics in clinical trials selectively target mechanisms in multi-drug resistant TB, gonorrhea, pneumonia etc. Tailored drugs are also being evaluated for challenging healthcare-associated infections. As pathogen-specific therapies gain ground, they will drive significant growth opportunities in the antimicrobial therapeutics sector by addressing current unmet needs more effectively.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it